Browsing Tag
REYOBIQ
5 posts
What REYOBIQ’s Phase 1 data means for the future of CNS-directed radiopharmaceutical platforms
What does REYOBIQ’s Phase 1 data reveal about the future of CNS-targeted radiopharmaceuticals? Explore the broader neuro-oncology implications.
What manufacturing scale-up means for REYOBIQ’s regulatory and clinical trajectory
Explore how Plus Therapeutics Inc. is scaling REYOBIQ manufacturing and what it means for regulatory approval and clinical success.
Can Moleculin Biotech, Inc. translate preclinical pancreatic cancer signals into clinical impact?
Explore how Plus Therapeutics Inc. is scaling REYOBIQ manufacturing and what it means for regulatory approval and clinical success.
Why pediatric ependymoma inclusion may be the bigger strategic signal for Plus Therapeutics
Why pediatric ependymoma may be the bigger strategic signal for Plus Therapeutics and what it means for REYOBIQ’s 2026 growth roadmap. Read more.
Investors eye Plus Therapeutics after promising ReSPECT-LM results and FDA fast-track push for REYOBIQ in brain metastases
See how Plus Therapeutics’ REYOBIQ delivered >75 percent benefit and no toxicity in its ReSPECT-LM trial—discover what this means for CNS cancer treatment and investors.